Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.63-9.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TENX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
TENX — officer change
Dated 2026-06-29
Amendments to employment agreements providing severance and other benefits.
Why it matters: The paper can show whether the new trial uses the patient group that showed the strongest walk gains in LEVEL. A clear plan can test that result.
Supportive ifThe paper sets a lower baseline walk limit near 333 meters. It names a clear main test and enrollment plan.
Worry ifThe paper keeps broad enrollment or gives no clear patient limit, primary test, or enrollment plan.
Why it matters: The company is still losing money and needs funds to run its trials. A shorter runway could put trial plans under pressure.
Watch forThe next company update keeps cash runway at least through Q2 2028.
Also watch forThe next company update moves the cash runway before Q2 2028.
Why it matters: The FDA’s view on patient selection may shape the next Phase 3 test. A clear path would support the program; a request for more evidence could delay it.
Watch forThe company says the FDA supports a LEVEL-2 plan. It enrolls patients who walked below 333 meters at baseline on the 6-minute walk test.
Also watch forThe FDA rejects that plan or asks for another trial before LEVEL-2 can support an application.
Why it matters: Steady enrollment is needed to reach the stated trial timeline. Delays could push back the next key result.
Watch forA company update reports active enrollment and site growth on a path to finish enrollment by end-2027.
Also watch forA company update reports enrollment delays or a timeline that goes past end-2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$278 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $896 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,258 loss on $10,000 · 92.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The full report can test whether the subgroup result holds up. LEVEL missed its main goal, so more support matters.
Watch forThe paper confirms a 6-minute walk gain of at least 20 meters versus placebo. Patients walked below 333 meters at trial start.
Also watch forThe paper reports that the below-333-meter group did not gain at least 20 meters versus placebo. Or it notes a key flaw in that result.